Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Real-Time Genomic Profiling Identifies Novel Mutations and Improved Therapy for Histiocytoses

Lynn Lee, MD, Anjelika Gasilina, Jayeeta Roychoudhury, PhD, Jason Clark, Francis X McCormack, MD, Joseph Gerald Pressey, MD, Robert B. Lorsbach, MD PhD, Siraj M Ali, MD PhD, Mark Bailey, MSc, Philip Stevens, PhD, Jeffrey S Ross, MD, Vincent A. Miller, MD, Nicolas Nassar, PhD, Ashish R Kumar, MBBS, PhD

Blood (2016) 128 (22): 2723.

https://doi.org/10.1182/blood.V128.22.2723.2723

Published: 2016

Journal Articles

LAMP5 - a Novel Target of MLL-Fusion Proteins Is Required for the Propagation of Leukemia

Gabriel Gracia-Maldonado, Jason Clark, James C. Mulloy, PhD, Ashish R Kumar, MBBS, PhD

Blood (2016) 128 (22): 1512.

https://doi.org/10.1182/blood.V128.22.1512.1512

Published: 2016

Journal Articles

A Xenograft Model of Lymphocyte-Independent, Effector-Driven Macrophage Activation SyndRome Amenable to Anti-CD33 and Anti-IL-6R Treatment

Mark Wunderlich, MS, Courtney Stockman, Mahima Devarajan, Navin Ravishankar, Christina Sexton, Ashish R Kumar, MBBS, PhD, Benjamin Mizukawa, MD, James C. Mulloy, PhD

Blood (2016) 128 (22): 3684.

https://doi.org/10.1182/blood.V128.22.3684.3684

Published: 2016

Journal Articles

JAK1/2 Inhibition As a Salvage Therapy for Steroid Refractory Acute and Chronic Graft Versus Host Disease in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients

Pooja Khandelwal, MD, Ashley Teusink-Cross, PharmD, Adam S. Nelson, MBBS, Christopher E. Dandoy, MD, Javier A. El-Bietar, MD, Rebecca A Marsh, MD, Ashish R Kumar, MBBS, PhD, Michael S Grimley, MD, Sonata Jodele, MD, Stella M Davies, MBBS, PhD, Kasiani C. Myers, MD

Blood (2016) 128 (22): 4568.

https://doi.org/10.1182/blood.V128.22.4568.4568

Published: 2016

Journal Articles

Susceptibility of AML to Chloroquine Therapy Is Independent of Autophagy

Xiaoyi Chen, PhDcandidate, Jason Clark, Jun-lin Guan, PhD, Ashish R Kumar, MBBS, PhD, Yi Zheng, PhD

Blood (2015) 126 (23): 1262.

https://doi.org/10.1182/blood.V126.23.1262.1262

Published: 2015

Journal Articles

MBNL1 As a New Therapeutic Target in MLL-Fusion Gene Leukemia

Svetlana S Itskovich, PhD, Jason Clark, James C. Mulloy, PhD, Matthew D Disney, Ashish R Kumar, MBBS, PhD

Blood (2015) 126 (23): 462.

https://doi.org/10.1182/blood.V126.23.462.462

Published: 2015

NARROW

Real-Time Genomic Profiling Identifies Novel Mutations and Improved Therapy for Histiocytoses

LAMP5 - a Novel Target of MLL-Fusion Proteins Is Required for the Propagation of Leukemia

A Xenograft Model of Lymphocyte-Independent, Effector-Driven Macrophage Activation SyndRome Amenable to Anti-CD33 and Anti-IL-6R Treatment

JAK1/2 Inhibition As a Salvage Therapy for Steroid Refractory Acute and Chronic Graft Versus Host Disease in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients

Susceptibility of AML to Chloroquine Therapy Is Independent of Autophagy

MBNL1 As a New Therapeutic Target in MLL-Fusion Gene Leukemia

Email alerts

ASH Publications

American Society of Hematology

Real-Time Genomic Profiling Identifies Novel Mutations and Improved Therapy for Histiocytoses

LAMP5 - a Novel Target of MLL-Fusion Proteins Is Required for the Propagation of Leukemia

A Xenograft Model of Lymphocyte-Independent, Effector-Driven Macrophage Activation SyndRome Amenable to Anti-CD33 and Anti-IL-6R Treatment

JAK1/2 Inhibition As a Salvage Therapy for Steroid Refractory Acute and Chronic Graft Versus Host Disease in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients

Susceptibility of AML to Chloroquine Therapy Is Independent of Autophagy

MBNL1 As a New Therapeutic Target in MLL-Fusion Gene Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only